Renaissance Capital logo

Arcellx Priced, Nasdaq: ACLX

Phase 1 biotech developing next-gen CAR-T therapies for blood cancers.

Industry: Health Care

Latest Trade: $83.42 0.00 (0.0%)

First Day Return: +12.0%

Return from IPO: +456.1%

Industry: Health Care

We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. We recently announced positive preliminary results from our ongoing Phase 1 clinical trial of CART-ddBCMA, our lead ddCAR product candidate, for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM), defined as patients with either minimal response or disease progression within 60 days of last treatment. As of the November 4, 2021 data cutoff date, of the 24 patients who had been dosed, 22 were evaluable for safety analysis and 19 were evaluable for efficacy analysis, based on follow-up of at least 1 and 3 months, respectively, following treatment using the 2016 International Myeloma Working Group (IMWG) uniform response criteria for MM. These evaluable patients comprised the dose escalation cohorts for the first dose level (DL1) (n=6) and the second dose level (DL2) (n=6) and a dose expansion cohort of DL1 (safety n=10, efficacy n=7).
more less
IPO Data
IPO File Date 01/14/2022
Offer Price $15.00
Price Range $15.00 - $17.00
Offer Shares (mm) 8.3
Deal Size ($mm) $124
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/03/2022
Offer Price $15.00
Price Range $15.00 - $17.00
Offer Shares (mm) 8.3
Deal Size ($mm) $124
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
BofA Securities
Leerink Partners
more
Company Data
Headquarters Gaithersburg, MD, United States
Founded 2014
Employees at IPO 78
Website www.arcellx.com

Arcellx (ACLX) Performance